Beigelman 2015.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 40 children (macrolide n = 20, placebo n = 20) Age in years (mean ± SD): 3.8 ± 2.9 Setting: secondary care
Interventions	Indication: respiratory syncytial virus bronchiolitis Type of macrolide: azithromycin Route: per oral Dose per day: 10 mg/kg once daily for 7 days, followed by 5 mg/kg once daily for an additional 7 days Duration of treatment: 14 days Total treatment dose: N/A
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: yes Adverse events ascertainment: contacting participants' families 3 times a week during the treatment period Adverse events: data reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Study supported by Washington University Institute of Clinical and Translational Sciences grant from the National Center for Advancing Translational Sciences and the Children’s Discovery Institute of Washington University and St Louis Children’s Hospital. Supported in part by CTSA grant and Siteman Comprehensive Cancer Center and NCI Cancer Center support grant
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of all participants, their families, investigators, and study staff
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 child lost to follow‐up
Selective reporting (reporting bias)	Low risk	Adverse events stated as an outcome, standardised ascertainment and adverse events reported.
Other bias	Low risk	None were identified.